25 related articles for article (PubMed ID: 31943207)
1. Targeting PPARγ/ NF-κB Signaling Pathway by Britannin, a Sesquiterpene Lactone from
Abdolmohammadi MH; Roozbehani M; Hamzeloo-Moghadam M; Heidari F; Fallahian F
Anticancer Agents Med Chem; 2023; 23(19):2102-2110. PubMed ID: 37723632
[TBL] [Abstract][Full Text] [Related]
2. Integrated Pharmaco-Bioinformatics Approaches and Experimental Verification To Explore the Effect of Britanin on Nonalcoholic Fatty Liver Disease.
Dou C; Zhu H; Xie X; Huang C; Cao C
ACS Omega; 2024 Feb; 9(7):8274-8286. PubMed ID: 38405493
[TBL] [Abstract][Full Text] [Related]
3. Research progress on antitumor mechanisms and molecular targets of Inula sesquiterpene lactones.
Cao F; Chu C; Qin JJ; Guan X
Chin Med; 2023 Dec; 18(1):164. PubMed ID: 38111074
[TBL] [Abstract][Full Text] [Related]
4. Britanin inhibits titanium wear particle‑induced osteolysis and osteoclastogenesis.
Kim JA; Lim S; Ihn HJ; Kim JE; Yea K; Moon J; Choi H; Park EK
Mol Med Rep; 2023 Nov; 28(5):. PubMed ID: 37732549
[TBL] [Abstract][Full Text] [Related]
5. Britanin relieves ferroptosis-mediated myocardial ischaemia/reperfusion damage by upregulating GPX4 through activation of AMPK/GSK3β/Nrf2 signalling.
Lu H; Xiao H; Dai M; Xue Y; Zhao R
Pharm Biol; 2022 Dec; 60(1):38-45. PubMed ID: 34860639
[TBL] [Abstract][Full Text] [Related]
6. Anticancer Targets and Signaling Pathways Activated by Britannin and Related Pseudoguaianolide Sesquiterpene Lactones.
Bailly C
Biomedicines; 2021 Sep; 9(10):. PubMed ID: 34680439
[TBL] [Abstract][Full Text] [Related]
7. Suppressive effects of britanin, a sesquiterpene compound isolated from Inulae flos, on mast cell-mediated inflammatory responses.
Park HH; Kim SG; Park YN; Lee J; Lee YJ; Park NY; Jeong KT; Lee E
Am J Chin Med; 2014; 42(4):935-47. PubMed ID: 25004884
[TBL] [Abstract][Full Text] [Related]
8. Britanin - a beacon of hope against gastrointestinal tumors?
Kajdanek A; Kołat D; Zhao LY; Kciuk M; Pasieka Z; Kałuzińska-Kołat Ż
World J Clin Oncol; 2024 Apr; 15(4):523-530. PubMed ID: 38689621
[TBL] [Abstract][Full Text] [Related]
9. In vivo antitumour activity of Britanin against gastric cancer through nuclear factor-κB-mediated immune response.
Shi K; Liu X; Du G; Cai X; Zhan Y
J Pharm Pharmacol; 2020 Apr; 72(4):607-618. PubMed ID: 31943207
[TBL] [Abstract][Full Text] [Related]
10. A novel natural product, britanin, inhibits tumor growth of pancreatic cancer by suppressing nuclear factor-κB activation.
Li K; Zhou Y; Chen Y; Zhou L; Liang J
Cancer Chemother Pharmacol; 2020 Apr; 85(4):699-709. PubMed ID: 32185482
[TBL] [Abstract][Full Text] [Related]
11. Britanin suppresses LPS-induced nitric oxide, PGE2 and cytokine production via NF-κB and MAPK inactivation in RAW 264.7 cells.
Park HH; Kim MJ; Li Y; Park YN; Lee J; Lee YJ; Kim SG; Park HJ; Son JK; Chang HW; Lee E
Int Immunopharmacol; 2013 Feb; 15(2):296-302. PubMed ID: 23270759
[TBL] [Abstract][Full Text] [Related]
12. The Antitumor Effects of Britanin on Hepatocellular Carcinoma Cells and its Real-Time Evaluation by In Vivo Bioluminescence Imaging.
Li H; Du G; Yang L; Pang L; Zhan Y
Anticancer Agents Med Chem; 2020; 20(9):1147-1156. PubMed ID: 32106805
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
